We are international
Donate
TEXT SIZE   

Carfilzomib Webcast Archive

06.13.10   ASCO 2010: Dose-escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) plus low-dose dexamethasone (Dex) (CRd) in relapsed/refractory multiple myeloma (R/R MM).
William Bensinger, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington, U.S.A.

06.13.10   ASCO 2010: Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency.
Ruben Niesvizky, MD
Weill Cornell Medical College
New York, New York, USA

06.13.10   ASCO 2010: Results of an ongoing open-label, phase II study of carfilzomib in patients with relapsed and/or refractory multiple myeloma (R/R MM).
Ravi Vij, MD
Washington University School of Medicine
Saint Louis, Missouri, USA